首页> 外文期刊>AIDS >Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
【24h】

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

机译:从感染利托那韦的蛋白酶抑制剂转为raltegravir的HIV感染患者的心血管生物标志物变化

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this strategy affects plasma biomarkers associated with atherosclerosis is unknown. Methods: We assessed 48-week changes in fasting lipids and several biomarkers including serum high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein 1 (MCP-1), osteoprotegerin, interleukin (IL) 6, IL-10, tumor necrosis factor alpha (TNF-α), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and P-selectin, adiponectin, insulin, and D-dimer in otherwise healthy, virologically suppressed HIV-infected patients treated with PI/r who randomly switched from PI/r to RAL or continued with PI/r in the SPIRAL trial. Biomarkers and lipids at baseline and 48-week changes between both study arms were compared. Correlations between changes in biomarkers and changes in lipids were also evaluated. Results: Of 273 patients initiating study drugs in the SPIRAL trial, 233 (119 RAL, 114 PI/r) remained on allocated therapy for 48 weeks and had sera available for the purpose of this substudy. Triglycerides (-28%, P < 0.0001), total (-14%, P < 0.0001), low-density lipoprotein (-9%, P = 0.0069), and high-density lipoprotein (-10%, P = 0.0017) cholesterol decreased in RAL relative to the PI/r group. Among biomarkers, hsCRP (-40%, P < 0.0001), MCP-1 (-20%, P = 0.0003), osteoprotegerin (-13%, P = 0.0024), IL-6 (-46%,P < 0.0001), TNF-α (-27%, P = 0.0011), insulin (-26%, P < 0.0001), and D-dimer (-8%, P = 0.0187) decreased in RAL relative to PI/r group, whereas IL-10 (+1%, P = 0.7773), ICAM-1 (-6%, P = 0.1255), VCAM-1(0%, P = 0.8671), E-selectin (-9%, P = 0.2174), P-selectin (-6%, P = 0.3865), and adiponectin (+8%, P = 0.2028) remained unchanged. Biomarkers and lipids changes at 48 weeks were weakly correlated. Conclusion: Switching from PI/r to RAL induced significant changes in several cardiovascular biomarkers that were not completely explained by lipid changes.
机译:背景:从增强的蛋白酶抑制剂(PI / r)切换到raltegravir(RAL)可获得比持续的PI / r更好的血浆脂质分布。该策略是否影响与动脉粥样硬化相关的血浆生物标志物尚不清楚。方法:我们评估了48周的空腹血脂变化和一些生物标志物,包括血清高敏C反应蛋白(hsCRP),单核细胞趋化蛋白1(MCP-1),骨保护素,白介素(IL)6,IL-10,肿瘤坏死因子α(TNF-α),细胞间粘附分子1(ICAM-1),血管细胞粘附分子1(VCAM-1),E-选择素和P-选择素,脂联素,胰岛素和D-二聚体经PI / r治疗的病毒学抑制HIV感染患者,从PI / r随机转换为RAL,或在SPIRAL试验中继续使用PI / r。比较了基线和两个研究组之间48周变化时的生物标志物和脂质。还评估了生物标志物变化与脂质变化之间的相关性。结果:在SPIRAL试验中,有273例开始研究药物的患者中,有233例(119 RAL,114 PI / r)继续接受分配治疗48周,并且有可用于该研究的血清。甘油三酸酯(-28%,P <0.0001),总数(-14%,P <0.0001),低密度脂蛋白(-9%,P = 0.0069)和高密度脂蛋白(-10%,P = 0.0017)相对于PI / r组,RAL中的胆固醇降低。在生物标志物中,hsCRP(-40%,P <0.0001),MCP-1(-20%,P = 0.0003),骨保护素(-13%,P = 0.0024),IL-6(-46%,P <0.0001)相对于PI / r组,RAL的TNF,α(-27%,P = 0.0011),胰岛素(-26%,P <0.0001)和D-二聚体(-8%,P = 0.0187)降低,而IL -10(+ 1%,P = 0.7773),ICAM-1(-6%,P = 0.1255),VCAM-1(0%,P = 0.8671),E-选择素(-9%,P = 0.2174), P-选择蛋白(-6%,P = 0.3865)和脂连蛋白(+ 8%,P = 0.2028)保持不变。 48周时生物标志物和脂质变化之间的相关性较弱。结论:从PI / r转换为RAL引起了几种心血管生物标志物的显着变化,但脂质变化并未完全解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号